Last reviewed · How we verify
Live, attenuated measles vaccine
At a glance
| Generic name | Live, attenuated measles vaccine |
|---|---|
| Sponsor | PATH |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (PHASE3)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
- A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001) (PHASE1)
- Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (PHASE2)
- Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Live, attenuated measles vaccine CI brief — competitive landscape report
- Live, attenuated measles vaccine updates RSS · CI watch RSS
- PATH portfolio CI